| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected and Quantified |
|---|
| Creation Date | 2006-05-18 08:39:36 UTC |
|---|
| Update Date | 2022-09-22 17:43:47 UTC |
|---|
| HMDB ID | HMDB0001927 |
|---|
| Secondary Accession Numbers | - HMDB0004997
- HMDB01927
- HMDB04997
|
|---|
| Metabolite Identification |
|---|
| Common Name | Diphenhydramine |
|---|
| Description | Diphenhydramine is a histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects. -- Pubchem; Pseudoephedrine is a phenethylamine, and an isomer of ephedrine. Pseudoephedrine is the International Nonproprietary Name (INN) of the (1S,2S)- diastereomer of ephedrine (which has 1R,2S- configuration). Other names are (+)-pseudoephedrine and D-pseudoephedrine (Reynolds, 1989). The enantiomer (-)-(1R,2R)-Pseudoephedrine has fewer side-effects, fewer central nervous system (CNS) stimulatory effects, does not reduce to d-methamphetamine, yet retains its efficacy as a decongestant.[citation needed] However, the patent holder for (-)-Pseudoephedrine (Pfizer/Warner-Lambert) has not yet sought or received government approval for its sale to the public.(US Patent 6,495,529); Treatment for urinary incontinence is an unlabeled use for these medications. Unlabeled use means doctors can use the medication to treat a condition other than that for which it was first approved by the U.S. Food and Drug Administration (FDA). These medications are approved by the FDA for the treatment of nasal congestion caused by colds or allergies. However it has also been successful in treating stress incontinence by increasing the pressure (tension) exerted by the muscles of the bladder neck and the urethra, which helps retain the urine within the bladder. Despite being one of the oldest antihistamines on the market, it is by and large the most effective antihistamine available, either by prescription or over-the-counter, and has been shown to exceed the effectiveness of even the latest prescription drugs. Consequently, it is frequently used when an allergic reaction requires fast, effective reversal of the (often dangerous) effects of a massive histamine release. However, it is not always the drug of choice for treating allergies. Like many other first generation antihistamines, is also a potent anticholinergic agent. This leads to profound drowsiness as a very common side-effect, along with the possibilities of motor impairment (ataxia), dry mouth and throat, flushed skin, rapid or irregular heartbeat (tachycardia), blurred vision at near point due to lack of accommodation (cycloplegia), abnormal sensitivity to bright light (photophobia), pupil dilatation, urinary retention, constipation, difficulty concentrating, short-term memory loss, visual disturbances, hallucinations, confusion, erectile dysfunction, and delirium. -- Wikipedia ;. |
|---|
| Structure | CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1 InChI=1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3 |
|---|
| Synonyms | | Value | Source |
|---|
| 2-(Benzhydryloxy)-N,N-dimethylethylamine | ChEBI | | 2-Diphenylmethoxy-N,N-demthylethanamine | ChEBI | | alpha-(2-Dimethylaminoethoxy)diphenylmethane | ChEBI | | beta-Dimethylaminoethanol diphenylmethyl ether | ChEBI | | beta-Dimethylaminoethyl benzhydryl ether | ChEBI | | Difenhidramina | ChEBI | | Diphenhydraminum | ChEBI | | N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine | ChEBI | | O-Benzhydryldimethylaminoethanol | ChEBI | | Restamin | Kegg | | a-(2-Dimethylaminoethoxy)diphenylmethane | Generator | | Α-(2-dimethylaminoethoxy)diphenylmethane | Generator | | b-Dimethylaminoethanol diphenylmethyl ether | Generator | | Β-dimethylaminoethanol diphenylmethyl ether | Generator | | b-Dimethylaminoethyl benzhydryl ether | Generator | | Β-dimethylaminoethyl benzhydryl ether | Generator | | Benadryl | HMDB | | Dobacen | HMDB | | Bendylate | HMDB | | Dimedrolum | HMDB | | Alledryl | HMDB | | Allergan | HMDB | | Allergina | HMDB | | Benzantin | HMDB | | Difenhydramine | HMDB | | Dimedrol | HMDB | | Dimethylamine benzhydryl ester | HMDB | | Diphamine | HMDB | | Diphantine | HMDB | | Allerdryl | HMDB | | Benzhydramine | HMDB | | Benhydramin | HMDB | | Diphenhydramine citrate (1:1) | HMDB | | Diphenylhydramine | HMDB | | 2-Diphenylmethoxy-N,N-dimethylethylamine | HMDB | | Benylin | HMDB | | Diphenylhydramin | HMDB | | Citrate, diphenhydramine | HMDB | | Diphenhydramine citrate | HMDB | | Diphenhydramine hydrochloride | HMDB | | Dormin | HMDB | | Hydrochloride, diphenhydramine | HMDB |
|
|---|
| Chemical Formula | C17H21NO |
|---|
| Average Molecular Weight | 255.3547 |
|---|
| Monoisotopic Molecular Weight | 255.162314299 |
|---|
| IUPAC Name | [2-(diphenylmethoxy)ethyl]dimethylamine |
|---|
| Traditional Name | diphenhydramine |
|---|
| CAS Registry Number | 147-24-0 |
|---|
| SMILES | CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1 |
|---|
| InChI Identifier | InChI=1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3 |
|---|
| InChI Key | ZZVUWRFHKOJYTH-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as diphenylmethanes. Diphenylmethanes are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Diphenylmethanes |
|---|
| Direct Parent | Diphenylmethanes |
|---|
| Alternative Parents | |
|---|
| Substituents | - Diphenylmethane
- Benzylether
- Tertiary aliphatic amine
- Tertiary amine
- Ether
- Dialkyl ether
- Organic nitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Organooxygen compound
- Organonitrogen compound
- Amine
- Aromatic homomonocyclic compound
|
|---|
| Molecular Framework | Aromatic homomonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 168 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.81 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.8211 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.24 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 34.5 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1632.0 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 298.0 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 169.7 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 189.8 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 148.2 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 445.2 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 474.6 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 440.8 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1168.2 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 372.0 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1208.7 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 262.9 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 348.4 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 281.7 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 269.2 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.0 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatized |
|---|